ABL Diagnostics Société anonyme (EPA:ABLD)

France flag France · Delayed Price · Currency is EUR
3.520
+0.160 (4.76%)
At close: Mar 13, 2026
Market Cap56.72M -56.0%
Revenue (ttm)6.23M +0.4%
Net Income463.36K +150.9%
EPSn/a
Shares Out16.11M
PE Ratio122.41
Forward PEn/a
Dividend0.05 (1.42%)
Ex-Dividend Daten/a
Volume4,529
Average Volume7,291
Open3.400
Previous Close3.360
Day's Range3.360 - 3.720
52-Week Range2.620 - 7.183
Beta-0.96
RSI50.33
Earnings DateMay 13, 2026

About EPA:ABLD

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA; ultragene assays for viral detection of SARS CoV-2, MonkeyPox, and Clostridium; microbiological specimen transport and collection kits, which inc... [Read more]

Sector Healthcare
CEO Chalom Sayada
Employees 19
Stock Exchange Euronext Paris
Ticker Symbol ABLD
Full Company Profile

Financial Performance

In 2024, EPA:ABLD's revenue was 5.87 million, a decrease of -5.16% compared to the previous year's 6.19 million. Earnings were 285,170, an increase of 424.58%.

Financial Statements